Results 121 to 130 of about 3,904 (178)

Dual-targeted therapy with risankizumab and upadacitinib in medically complex Crohn's disease. [PDF]

Crohns Colitis 360
Fear EN, McDonald BD, Kennedy MS, Mathew AJ, McMillan RH, Fine ZD, McDermott AR, Choi D, Kellar A, Rubin DT.   +9 more
europepmc   +1 more source

Effects of Guselkumab on Structural Damage Progression in Patients with Active Psoriatic Arthritis. [PDF]

Adv Ther
Ritchlin CT, Coates LC, Mease PJ, van der Heijde D, Rahman P.   +4 more
europepmc   +1 more source

Psoriatic Arthritis: Therapeutic Advances and Novel Treatment Strategies-A Scoping Review. [PDF]

Life (Basel)
Athanassiou L, Kostoglou-Athanassiou I, Kaiafa G, Savopoulos C, Shoenfeld Y, Athanassiou P.   +5 more
europepmc   +1 more source

Lung abscess as an adverse effect of Risankizumab. [PDF]

Eur Clin Respir J
Kazi Z, Jesin S, Ghimire S, Lewis TA, Donenfeld T, Clements K, Pascal W.   +6 more
europepmc   +1 more source

Chronic Plaque Psoriasis With Persistent Facial Involvement Successfully Treated With Risankizumab: A Case Report. [PDF]

Cureus
AlQusaimi R, AlRujaib F, AlSharhan F, Alassaf S, Khoursheed L, Abdulrahman F, AlAwadhi D.   +6 more
europepmc   +1 more source

A randomized phase 2 clinical trial to treat moderate-to-severe plaque psoriasis patients with high-induction dosing of risankizumab. [PDF]

Nat Commun
Blauvelt A, Jiang R, Shi L, Tsoi LC, Bogle R, Fox J, Gharaee-Kermani M, Billi AC, Matheson RT, Photowala H, Gudjonsson JE, Ehst BD.   +11 more
europepmc   +1 more source

Efficacy and safety of risankizumab in patients with moderately to severely active Crohn's disease: interim results from the SEQUENCE open-label extension study. [PDF]

J Crohns Colitis
Peyrin-Biroulet L, Atreya R, Danese S, Lindsay JO, Chapman JC, Anschutz T, Huang X, Zambrano J, van Haaren S, Joshi N, Duan WR, Cross RK.   +11 more
europepmc   +1 more source

Psoriasis in Difficult-to-Treat Areas: A Multicentre, Real-World Retrospective Study Analyzing the Impact of Non-Invasive Imaging Techniques (Dermoscopy, Reflectance Confocal Microscopy and Optical Coherence Tomography) to Monitor the Effectiveness of Risankizumab in the Treatment of Plaque Psoriasis of the Legs. [PDF]

Clin Pract
Dattola A, Rossi R, Rizzuto G, Caldarola G, De Luca E, Lora V, Giordano D, Persechino S, Bonifati C, Orsini D, Graceffa D, Zangrilli A, Pagnanelli G, Tribuzi P, Mazzotta A, Moretta G, Micheli A, Provini A, Zanframundo S, Panasiti V, Pellacani G, Potenza C, Richetta AG, Bernardini N.   +23 more
europepmc   +1 more source

Comparative risk of psoriatic arthritis in psoriasis patients on immunomodulators. [PDF]

Proc (Bayl Univ Med Cent)
Schmidt M, Dowdle TS, Golovko G, Munoz A.   +3 more
europepmc   +1 more source

Real-World Benefit of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis: Findings from a Systematic Literature Review and Meta-Analysis. [PDF]

Dermatol Ther (Heidelb)
Gottlieb S, Farberg AS, Bhatia N, Fazeli MS, Hofer K, Lam O, Barghout V, Mathew J, Ferro TJ.   +8 more
europepmc   +1 more source